Conformable Thoracic Endograft Versus Traditional Endograft for Acute Type B Aortic Dissection

Jingyang Luan,Le Mao,Yimin Yang,Si Yi,Yuanqing Kan,Tianyue Pan,Ting Zhu,Weiguo Fu
DOI: https://doi.org/10.2139/ssrn.3958702
2021-01-01
SSRN Electronic Journal
Abstract:Background: The objective of this study was to evaluate the safety, efficacy, and outcomes of the conformable thoracic aortic endograft (Conformable TAG Thoracic Endoprosthesis [CTAG]; W. L. Gore & Associates, Flagstaff, Ariz) for acute type B aortic dissection, by comparing it with a traditional graft stent (Valiant Captivia thoracic stent graft; Medtronic Inc, Santa Rosa, Calif).Methods: All patients with acute type B aortic dissection who underwent thoracic aortic endovascular repair from January 2008 to December 2018 in our center were retrospectively reviewed. From this population, 106 propensity-matched pairs of patients were generated from 129 individuals using CTAG and from 284 patients using Captivia. Mortality, reintervention, and TEVAR-related complications were analyzed for both patient groups.Results: The median follow-up was 41.7 (0.07–132.37) months. There was no significant difference in mortality rate (9 [7.0%] vs. 36 [12.7%], P= .433) and re-intervention rate (3 [2.3%] vs. 20 [7.0%], P= .301) between CTAG and Captivia group. The CTAG was independently associated with a lower incidence of distal stent graft-induced new entry tear (adjusted hazard ratio: 0.28; 95% CI: 0.09–0.94). The CTAG was associated with a lower risk of type I endoleak in patients with type III arch (adjusted hazard ratio: 0.04; 95% CI: 0.01–0.44).Conclusions: The survival and re-intervention rate of CTAG stents are comparable to Captivia stents. The rate of distal stent graft-induced new entry tear was significantly lower with the CTAG than with the Captivia stent, even with larger oversizing.
What problem does this paper attempt to address?